

Maggie Cheang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11272071/publications.pdf>

Version: 2024-02-01

13
papers

3,964
citations

933447

10
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

5954
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5367-5374.	7.0	2,393
2	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 302ra133.	12.4	889
3	Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1443-1454.	10.7	159
4	GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 365-373.	2.5	125
5	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 131-142.	2.5	117
6	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. <i>Breast Cancer Research</i> , 2005, 7, R796-807.	5.0	83
7	Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival. <i>Cancer Research</i> , 2004, 64, 286-291.	0.9	82
8	The use of digital pathology and image analysis in clinical trials. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 81-90.	3.0	71
9	Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 91-99.	3.0	21
10	Training and accreditation standards for pathologists undertaking clinical trial work. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 100-107.	3.0	10
11	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2 ⁺ Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 163-174.	7.0	8
12	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. <i>Modern Pathology</i> , 2008, 21, 1413-1420.	5.5	3
13	Abstract PS5-01: Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial. <i>Cancer Research</i> , 2021, 81, PS5-01-PS5-01.	0.9	3